{"id":"https://openalex.org/W1506967446","doi":"https://doi.org/10.1111/j.1365-2133.2012.10947.x","title":"Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-\u03b1 therapies: a case series","display_name":"Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-\u03b1 therapies: a case series","publication_year":2012,"publication_date":"2012-03-17","ids":{"openalex":"https://openalex.org/W1506967446","doi":"https://doi.org/10.1111/j.1365-2133.2012.10947.x","mag":"1506967446","pmid":"https://pubmed.ncbi.nlm.nih.gov/22428935"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2133.2012.10947.x","doi":"https://doi.org/10.1111/j.1365-2133.2012.10947.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2133.2012.10947.x","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022949271","display_name":"Muriel Sadlier","orcid":"https://orcid.org/0000-0001-5544-757X","observed_orcids":["https://orcid.org/0000-0001-5544-757X"]},"institutions":[{"id":"https://openalex.org/I4210115218","display_name":"St. Vincent's University Hospital","ror":"https://ror.org/029tkqm80","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210115218"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"M. Sadlier","raw_affiliation_strings":["Department of Dermatology, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, Ireland E\u2010mail:","Department of Dermatology; St Vincent's University Hospital; Elm Park Dublin 4 Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, Ireland E\u2010mail:","institution_ids":["https://openalex.org/I4210115218"]},{"raw_affiliation_string":"Department of Dermatology; St Vincent's University Hospital; Elm Park Dublin 4 Ireland","institution_ids":["https://openalex.org/I4210115218"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110957033","display_name":"Aoife Lally","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115218","display_name":"St. Vincent's University Hospital","ror":"https://ror.org/029tkqm80","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210115218"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"A. Lally","raw_affiliation_strings":["Department of Dermatology, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, Ireland E\u2010mail:","Department of Dermatology; St Vincent's University Hospital; Elm Park Dublin 4 Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, Ireland E\u2010mail:","institution_ids":["https://openalex.org/I4210115218"]},{"raw_affiliation_string":"Department of Dermatology; St Vincent's University Hospital; Elm Park Dublin 4 Ireland","institution_ids":["https://openalex.org/I4210115218"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073196144","display_name":"Brian Kirby","orcid":"https://orcid.org/0000-0001-7596-892X","observed_orcids":["https://orcid.org/0000-0001-7596-892X"]},"institutions":[{"id":"https://openalex.org/I4210115218","display_name":"St. Vincent's University Hospital","ror":"https://ror.org/029tkqm80","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210115218"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"B. Kirby","raw_affiliation_strings":["Department of Dermatology, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, Ireland E\u2010mail:","Department of Dermatology; St Vincent's University Hospital; Elm Park Dublin 4 Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, Ireland E\u2010mail:","institution_ids":["https://openalex.org/I4210115218"]},{"raw_affiliation_string":"Department of Dermatology; St Vincent's University Hospital; Elm Park Dublin 4 Ireland","institution_ids":["https://openalex.org/I4210115218"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210115218"],"apc_list":{"value":3731,"currency":"GBP","value_usd":4920},"apc_paid":null,"fwci":0.3898,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.56790123,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"167","issue":"4","first_page":"937","last_page":"938"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9613999724388123,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9613999724388123,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.009600000455975533,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12433","display_name":"Skin Diseases and Diabetes","score":0.008799999952316284,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.8009999990463257},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.8539999723434448},{"id":"https://openalex.org/keywords/tumor-necrosis-factor-inhibitors","display_name":"tumor necrosis factor inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/cancer-risk","display_name":"cancer risk","score":0.7020000219345093},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.7960000038146973},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":0.9980000257492065},{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":0.9200000166893005},{"id":"https://openalex.org/keywords/long-term-drug-safety","display_name":"long-term drug safety","score":0.7009999752044678}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7130861878395081},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5422147512435913},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.4912700057029724},{"id":"https://openalex.org/C3017595490","wikidata":"https://www.wikidata.org/wiki/Q17006263","display_name":"University hospital","level":2,"score":0.4790162444114685},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.473537415266037},{"id":"https://openalex.org/C161191863","wikidata":"https://www.wikidata.org/wiki/Q199655","display_name":"Library science","level":1,"score":0.3374851942062378},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068800","descriptor_name":"Etanercept","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D009765","descriptor_name":"Obesity","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D015535","descriptor_name":"Arthritis, Psoriatic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018124","descriptor_name":"Receptors, Tumor Necrosis Factor","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2133.2012.10947.x","doi":"https://doi.org/10.1111/j.1365-2133.2012.10947.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2133.2012.10947.x","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},{"id":"pmid:22428935","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22428935","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The British journal of dermatology","raw_type":"Case Reports"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":6,"referenced_works":["https://openalex.org/W1608678290","https://openalex.org/W1983934840","https://openalex.org/W2034825007","https://openalex.org/W2073601928","https://openalex.org/W2116640162","https://openalex.org/W2166305732"],"related_works":["https://openalex.org/W3174469391","https://openalex.org/W7167514491","https://openalex.org/W111625132","https://openalex.org/W4404798452","https://openalex.org/W2027953952","https://openalex.org/W4408174601","https://openalex.org/W2011814953","https://openalex.org/W2540285259","https://openalex.org/W4240303292","https://openalex.org/W2906460626"],"abstract_inverted_index":{"Funding:":[0],"none.":[1],"Conflicts":[2],"of":[3,9,41,51,69,126,193,209],"interest:":[4],"B.K.":[5],"is":[6],"in":[7,62,114,137,143,159],"receipt":[8],"unrestricted":[10],"research":[11],"grants":[12],"from":[13],"Abbott":[14,28],"Ltd.,":[15,29],"Pfizer":[16],"and":[17,19,25,35,56,102,146,162],"Janssen,":[18,31],"works":[20],"as":[21],"an":[22],"advisor":[23],"to":[24,73,150,168],"consultant":[26],"for":[27,132],"Pfizer,":[30],"Merck":[32],"Sharp":[33],"Dohme":[34],"Leo":[36],"Pharmaceuticals.":[37],"Madam,":[38],"The":[39],"use":[40],"tumour":[42],"necrosis":[43],"factor":[44],"inhibitors":[45],"(TNFi)":[46],"has":[47,58,71],"revolutionized":[48],"the":[49,65,163],"treatment":[50],"psoriasis.":[52],"While":[53],"their":[54],"efficacy":[55],"safety":[57],"been":[59],"evaluated":[60],"extensively":[61],"clinical":[63],"trials,1":[64],"potential":[66],"long\u2010term":[67],"risk":[68],"malignancy":[70,87],"yet":[72],"be":[74],"established.":[75],"We":[76],"report":[77],"five":[78],"obese":[79,119],"patients":[80],"with":[81,91,100,120],"severe":[82],"psoriasis":[83,101,134,141,157],"who":[84,105],"developed":[85,182],"a":[86,96,121,183,196],"while":[88],"being":[89],"treated":[90],"TNFi.":[92],"Patient":[93],"1":[94],"was":[95,106,118,148,166,206],"56\u2010year\u2010old":[97],"male":[98],"nonsmoker":[99],"psoriatic":[103],"arthritis":[104],"commenced":[107],"on":[108,188],"etanercept":[109],"50":[110],"mg":[111,154,170],"twice":[112],"weekly":[113],"October":[115],"2004.":[116],"He":[117],"body":[122],"mass":[123],"index":[124],"(BMI)":[125],"34\u00b74":[127],"kg":[128],"m\u22122.":[129],"Previous":[130],"treatments":[131],"his":[133,189],"are":[135],"listed":[136],"Table":[138],"1.":[139],"His":[140,156],"deteriorated":[142],"August":[144],"2006":[145],"he":[147,181],"switched":[149],"adalimumab":[151,164],"monotherapy":[152],"(40":[153],"fortnightly).":[155],"flared":[158],"April":[160],"2008":[161],"dose":[165],"increased":[167],"40":[169],"weekly.":[171],"In":[172],"January":[173],"2011,":[174],"6\u00b75":[175],"years":[176],"after":[177],"commencing":[178],"TNFi":[179],"therapy,":[180],"rapidly":[184],"enlarging":[185],"violaceous":[186],"nodule":[187],"forehead.":[190],"Histopathological":[191],"analysis":[192],"this":[194],"revealed":[195],"primary":[197],"cutaneous":[198],"follicle":[199],"centre":[200],"B\u2010cell":[201],"non\u2010Hodgkin":[202],"lymphoma":[203],"(NHL).":[204],"There":[205],"no":[207],"evidence":[208],"extracutaneous":[210],"lymphoma.":[211]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}